Skip to main content
TipRanks
Go Ultimate75% OFF

CytomX Therapeutics (CTMX) Stock Statistics & Valuation Metrics

1,005 Followers

Total Valuation

CytomX Therapeutics has a market cap or net worth of $444.73M. The enterprise value is $251.46M.

Market Cap
$444.73M
Enterprise Value
$251.46M

Share Statistics

CytomX Therapeutics has 218,004,910 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
218,004,910
Owned by Insiders
0.96%
Owned by Institutions
45.75%

Financial Efficiency

CytomX Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -20.48%.

Return on Equity (ROE)
-0.18
Return on Assets (ROA)
-0.11
Return on Invested Capital (ROIC)
-20.48%
Return on Capital Employed (ROCE)
-0.21
Revenue Per Employee
1.10M
Profits Per Employee
-251.71K
Employee Count
69
Asset Turnover
0.50
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of CytomX Therapeutics is -4.52. CytomX Therapeutics’s PEG ratio is 0.03.

PE Ratio
-4.52
PS Ratio
31.71
PB Ratio
1.57
Price to FCF
-8.72
Price to Operating Cash Flow
-8.90
PEG Ratio
0.03

Income Statement

In the last 12 months, CytomX Therapeutics had revenue of 76.20M and earned -17.37M in profits. Earnings per share was -0.15.

Revenue
76.20M
Gross Profit
76.20M
Operating Income
-22.36M
Pretax Income
-17.13M
Net Income
-17.37M
EBITDA
-15.75M
Earnings Per Share (EPS)
-0.15

Cash Flow

In the last 12 months, operating cash flow was -50.21M and capital expenditures -790,000, giving a free cash flow of -51.00M billion.

Operating Cash Flow
-50.21M
Free Cash Flow
-51.00M
Free Cash Flow per Share
-0.23

Dividends & Yields

CytomX Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-11.47%
Earnings Yield
-19.11%

Stock Price Statistics

Beta
2.98
52-Week Price Change
-47.15%
50-Day Moving Average
2.60
200-Day Moving Average
3.69
Relative Strength Index (RSI)
39.35
Average Volume (3m)
4.20M

Important Dates

CytomX Therapeutics upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Feb 24, 2027
Ex-Dividend Date
―

Financial Position

CytomX Therapeutics as a current ratio of 3.09, with Debt / Equity ratio of 4.28%

Current Ratio
3.09
Quick Ratio
3.09
Debt to Market Cap
0.01
Net Debt to EBITDA
0.53
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, CytomX Therapeutics has paid 238.00K in taxes.

Income Tax
238.00K
Effective Tax Rate
-0.01

Enterprise Valuation

CytomX Therapeutics EV to EBITDA ratio is -4.74, with an EV/FCF ratio of -8.14.

EV to Sales
29.60
EV to EBITDA
-4.74
EV to Free Cash Flow
-8.14
EV to Operating Cash Flow
-8.27

Balance Sheet

CytomX Therapeutics has $347.98M in cash and marketable securities with $4.39M in debt, giving a net cash position of $343.59M billion.

Cash & Marketable Securities
$347.98M
Total Debt
$4.39M
Net Cash
$343.59M
Net Cash Per Share
$1.58
Tangible Book Value Per Share
$1.29

Margins

Gross margin is 98.21%, with operating margin of -676.46%, and net profit margin of -608.98%.

Gross Margin
98.21%
Operating Margin
-676.46%
Pretax Margin
-607.31%
Net Profit Margin
-608.98%
EBITDA Margin
-624.01%
EBIT Margin
-632.73%

Analyst Forecast

The average price target for CytomX Therapeutics is $13.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$13.00
Price Target Upside
537.25% Upside
Analyst Consensus
Strong Buy
Analyst Count
6
Revenue Growth Forecast
-87.66%
EPS Growth Forecast
-210.45%

Scores

Smart Score
7
AI Score
45